Skip to main content
. Author manuscript; available in PMC: 2016 Sep 22.
Published in final edited form as: J Leuk (Los Angel). 2015 Apr 21;3(2):178. doi: 10.4172/2329-6917.1000178

Figure 4. Lenalidomide enhanced anti-tumor activities of XBP1-CTL memory cells against solid tumor cells.

Figure 4

XBP1-CTL (n=3) treated with lenalidomide (5 μm, 4 days) were analyzed for their functional activities against HLA-A2+ breast cancer cell (MDA-MB231), pancreatic cancer cell (Panc1) or colon cancer (SW480) cells. (A) Lenalidomide increased IFN-γ production by total CD3+CD8+ T cells in response to the respective cancer cells. High levels of granzyme B upregulation and IFN-γ production were detected within the CD45RO+ memory CTL population in response to (B) MDA-MB231, (C) Panc1 or (D) SW480 tumor cells. Results are expressed as ‘% positive cells’ of the specific CD3+CD8+ T cell memory subsets for either single or poly-functional anti-tumor activity.